Potential target antigens for immunotherapy in human pancreatic cancer
- 18 July 2007
- journal article
- Published by Elsevier in Cancer Letters
- Vol. 252 (2), 290-298
- https://doi.org/10.1016/j.canlet.2007.01.003
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Inhibition of αvβ3 Integrin Survival Signaling Enhances Antiangiogenic and Antitumor Effects of RadiotherapyClinical Cancer Research, 2005
- Epidemiology and Prevention of Pancreatic CancerJapanese Journal of Clinical Oncology, 2004
- Development of Immunotherapy for Pancreatic CancerPancreas, 2004
- Cancer/testis antigens: an expanding family of targets for cancer immunotherapyImmunological Reviews, 2002
- Analysis of the B‐cell repertoire against antigens expressed by human neoplasmsImmunological Reviews, 2002
- A Phase I Trial of an HLA-A1 Restricted MAGE-3 Epitope Peptide with Incomplete Freundʼs Adjuvant in Patients with Resected High-Risk MelanomaJournal of Immunotherapy, 1999
- Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by geneMAGE-3 and presented by HLA-A1International Journal of Cancer, 1999
- A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screeningProceedings of the National Academy of Sciences, 1997
- Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells.Proceedings of the National Academy of Sciences, 1995
- Pancreatic CarcinomaNew England Journal of Medicine, 1992